AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

GlycoMimetics to Present at Upcoming Investor Conferences

April 4, 2019

ROCKVILLE, Md.--(BUSINESS WIRE)--Apr 4, 2019--GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that senior management will present corporate updates at two upcoming investor conferences in April. Details are as follows:

HC WAINWRIGHT GLOBAL LIFE SCIENCES CONFERENCE
Who: Chief Financial Officer Brian Hahn
When:  Tuesday, April 9 at 2:10 p.m. (GMT)
Where:  London, UK

18 TH ANNUAL NEEDHAM HEALTHCARE CONFERENCE
Who: Chief Executive Officer Rachel King
When:  Wednesday, April 10 at 3:30 p.m. (ET)
Where:  New York, NY

To access the live webcast and subsequent archived recordings for each of these presentations, please visit the GlycoMimetics website at  www.glycomimetics.com.

About GlycoMimetics, Inc.

GlycoMimetics is a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics’ most advanced drug candidate, rivipansel, a pan-selectin antagonist, is being developed for the treatment of vaso-occlusive crisis in sickle cell disease and is being evaluated in a Phase 3 clinical trial being conducted by its strategic collaborator, Pfizer. GlycoMimetics’ wholly owned drug candidate, uproleselan, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a potential treatment for AML and is being evaluated across a range of patient populations including a company-sponsored Phase 3 trial in relapsed/refractory AML. GlycoMimetics has also completed a Phase 1 clinical trial with a third drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at  www.glycomimetics.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190404005543/en/

CONTACT: Investor Contact:

Shari Annes

Phone: 650-888-0902

Email:sannes@annesassociates.comMedia Contact:

Jamie Lacey-Moreira

Phone: 410-299-3310

Email:jamielacey@presscommpr.com

KEYWORD: UNITED KINGDOM UNITED STATES EUROPE NORTH AMERICA MARYLAND NEW YORK

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY INFECTIOUS DISEASES PHARMACEUTICAL OTHER HEALTH GENERAL HEALTH

SOURCE: GlycoMimetics, Inc.

Copyright Business Wire 2019.

PUB: 04/04/2019 04:00 PM/DISC: 04/04/2019 04:00 PM

http://www.businesswire.com/news/home/20190404005543/en